MAR 2 4 2004 H

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Tetsuo NAGANO et al.

Group Art Unit: 1743

Appln. No.: 10/744,007

Examiner: Unknown

Filed: December 24, 2003

For : DIAMINORHODAMINE DERIVATIVE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with Applicants' duty of disclosure under 37 C.F.R. 1.56, Applicants hereby submit the following Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98, and in conformance with MPEP 609 and 37 C.F.R. 1.98(d).

Applicants hereby make of record the disclosure statement filed August 20, 2001, and the Information cited by the Examiner in the Office Action mailed February 4, 2003 in parent Application No. 09/641,350.

The Examiner is respectfully requested to consider the documents cited in the parent application, and to make the documents cited therein of record in the instant application.

Applicants note that copies of documents cited in the above-mentioned disclosure statement have been submitted in parent Application No. 09/641,350. Accordingly, pursuant to 37 C.F.R. 1.98(d) copies of the documents are not being submitted herewith, and the Examiner is invited to review and consider the documents in the parent application. Of course, should any of the

P24350.A01

documents not be readily available to the Examiner, the Examiner is requested to contact the undersigned and additional copies will be submitted.

For the convenience of the Examiner, the above-noted documents cited in the parent applications are listed on the attached Forms PTO-1449. The Examiner is requested to initial the Forms PTO-1449, and to return the initialed copy with the next communication from the U.S. Patent and Trademark Office.

Should the Examiner have any questions or comments regarding this matter, the undersigned may be contacted at the below-listed telephone number.

Respectfully submitted, Tetsuo NAGANO et al.

Telsuo MAGANO el a

Bruce H. Bernstein

Agno 33,04

Reg. No. 29,027

March 24, 2004 GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191

(703) 716-1191

P24350.P04

Form PTO-1449

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. P24350

Applicant

Serial No. 10/744,007

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

not considered. Include copy of this form with next communication to applicant.

BY APPLICANT Tetsuo NAGANO et al.

(Use several sheets if necessary)

Filing Date Group
December 24, 2003 1743

								•		U.S. PATENT	DOCUMENTS				
EXAMINER INITIAL		N	DOCUMENT NUMBER				Т		DATE				G DATE OPRIATE		
		5	5 8 7 4 5 9 0			0	02/23/99	NAGANO et al.							
		6	6 2 0 1 1 3 4			4	03/2001	NAGANO et al.							
		6	4	6	9	0	5	1	10/2002	NAGANO et al.					
		.							F	OREIGN PATE	NT DOCUMENTS	1			
			DOCUMENT NUMBER						DATE	СО	UNTRY	CLASS	SUBCLASS	TRANS YES	LATION NO
	9	-	0	4	3	1	5	3	02/14/97	JAPAN					
	1	0	2	2	6	6	8	8	08/25/98	JAPAN					
	9	9	/	0	1	4	4	7	01/14/99	W.I.P.O.					
	0	1	/	6	3	2	6	5	08/2001	W.I.P.O.					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)															
		1	Eı	English Language Abstract of JP 9-043153											
		2	Eı	English Language Abstract of JP 10-226688											
		3	CI	Chemistry Today [Gendai Kagaku], April, pp. 25-29 (1994).											
		4	PA	PALMER et al., <u>Nature</u> , Vol. 327, pp. 524-526 (1987).											
		5	K	KELM et al., Circulation Research, Vol. 66, No. 6, pp. 1561-1575 (1990).											
		6	SI	SHIBUKI, Neuroscience Research 9, pp. 69-76 (1990).											
		7	М	MALINSKI et al., <u>Nature</u> , Vol. 358, pp. 676-678 (1992).											
		8	G:	GREEN et al., Analytical Biochemistry, Vol. 126, pp. 131-138 (1982).											
		9	" <i>A</i>	"Approaches From The Newest Medicine [Saishin Igaku Kara No Approach] 12, NO", Ed. by Noboru Toda, pp. 42-52.											
	1	0	A	ARCHER, The FASEB Journal, Vol.7, pp. 349-360 (1993).											
	1	ı	ST	STAINTON, Analytical Chemistry, Vol. 46, No. 11, p. 1616, (1974.											
	1	2	SA	SAWICKI et al., Microchemical Journal, Vol. 16, pp. 657-672 (1971).											
	1	3	W	WIERSMA, Analytical Letters, Vol. 3, No. 3, pp. 123-132 (1970).											
	1	4	D.	DAMIANI, <u>Talanta</u> , Vol. 33, No. 8, pp. 649-652 (1986).											
EXAMINER											DATE CONSIDERE	ED			

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and

P24350.P04

RADEMAR

Form	DT	\sim	1440

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. P24350

Serial No. 10/744,007

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant Tetsuo NAGANO et al.

		(03	e several sheets if necessary)	Filing Date December 24, 2003	Group 1743					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)										
	1	5	MISKO, Analytical Biochemistry, 214, pp. 11-16 (1993).							
	ı	6	<u>DOJIN News,</u> No. 74, p. 18 (1995).							
	1	7	SAWICKI, <u>Analytical Letters</u> , 4, (11), pp. 761-775 (1971).							
	1	8	MAEDA et al., Journal of Leukocyte Biology, Vol. 56, pp. 588-592 (1994.)							
	<u> </u>	9	AKAIKE et al., <u>Biochemistry</u> , Vol. 32, pp. 827-832 (1993).							
	2	0	Tokyo Chemical Industry Co., Ltd., Organic Chemicals Catalog, 32, (1994).							
	2	1	KIKUCHI et al., <u>Biol. Pharm. Bull.</u> , 19, (4), pp. 649-651 (1996).							
	2	2	FLEMING et al., Circulation Research, Vol. 74, No. 6 pp. 1220-1226 (1994).							
]	2	3	Abstracts of Papers, Part 1, 218th ACS National Meeting, American Chemical Society, August 22-26 (1999).							
	2	4	KOJIMA et al., Angew Chem. Int. Ed., 38, No. 21 pp. 3209-3212 (1999).							
	2	5	KOJIMA et al., <u>Tetrahedron Letters</u> , 41, pp. 69-72 (2000).							
:	2	6	Analytical Chemistry. "Bioimaging of Nitric Oxide with Fluorescent Indicators Based on the Rhodamine							
			Chromophore". KOJIMA et al March 2001.							
	_			·						
	_									
	4									
	4	_								
	-	_	·	~						
	4									
	\dashv	\dashv								
	\dashv			·						
	\dashv									
	+									
	+									
	+									
	\dashv		· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·					
EXAMINER				DATE CONSIDERED						

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.